胃癌组织中表皮生长因子受体和Her-2的表达及其临床意义

 目的　检测胃癌组织中表皮生长因子受体（EGFR）、Her-2的表达，探讨其在胃癌发生发展及侵袭、转移中的作用，寻找评价胃癌预后的有效指标。方法　采用免疫组织化学方法检测胃癌组织中EGFR、Her-2的表达，分析EGFR、Her-2的表达与胃癌患者临床病理特征及预后的关系。结果　在84例胃癌组织中，EGFR、Her-2过表达率分别为27.4 %和32.1 %；Ⅲ+Ⅳ期患者EGFR、Her-2过表达率明显高于Ⅰ+Ⅱ期患者（P值分别为0.014和0.005）；T3+T4期Her-2的阳性率明显高于T1+T2期（P＝0.033）；淋巴结阳性者Her-2的阳性率明显高于阴性者（P＝0.033）。EGFR、Her-2过表达者总生存及无进展生存期明显低于低表达者。结论　检测胃癌组织中的EGFR和Her-2表达，有助于胃癌恶性程度的判断和预后的评估。

Expression and clinical significance of EGFR and Her-2 in gastric cancer

Objective To analyze the relationship between the survival and expressions of EGFR and Her-2, and explore the prognostic significance of EGFR and Her-2 in gastric cancer patient by detecting the expressions of EGFR and Her-2 in gastric cancer specimens. Methods EGFR and Her-2 were detected by immunohistochemistry. The relation between their expressions with their clinical characteristics and prognosis were analyzed. Results The over-expression rates of EGFR and Her-2 are 27.4 % and 32.1% respectively in 84 cases. The over-expression rates of EGFR and Her-2 in patients with Ⅲ + Ⅳ stages were significantly higher than those with Ⅰ + Ⅱ stages(respectively, P =0.014 and P =0.005). The positive rate in patients with T3+T4 stages were significantly higher than those with T1+T2 stages (P=0.033); and the positive rate in patients with positive lymph node was higher significantly than that with negative (P =0.033). The OS and PFS in over-expression patients were significantly longer than low-expression. Conclusion The overexpression of EGFR and Her-2 could be used to evaluate the degree of differentiation and prognosis of patients with gastric cancer.